Sarepta Therapeutics (SRPT) Pares Gains Following FDA Approval

September 19, 2016 10:14 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Sarepta Therapeutics (NASDAQ: SRPT) gives up big chunk of gains following approval. Shares up 53% after trading up over 80%.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Momentum Movers, Trader Talk

Add Your Comment